BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 29861388)

  • 21. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.
    Iepsen EW; Lundgren JR; Hartmann B; Pedersen O; Hansen T; Jørgensen NR; Jensen JE; Holst JJ; Madsbad S; Torekov SS
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2909-17. PubMed ID: 26043228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial.
    Jensen SBK; Sørensen V; Sandsdal RM; Lehmann EW; Lundgren JR; Juhl CR; Janus C; Ternhamar T; Stallknecht BM; Holst JJ; Jørgensen NR; Jensen JB; Madsbad S; Torekov SS
    JAMA Netw Open; 2024 Jun; 7(6):e2416775. PubMed ID: 38916894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.
    Lin CH; Shao L; Zhang YM; Tu YJ; Zhang Y; Tomlinson B; Chan P; Liu Z
    Expert Opin Pharmacother; 2020 Feb; 21(3):275-285. PubMed ID: 31790314
    [No Abstract]   [Full Text] [Related]  

  • 24. Liraglutide in the treatment of obesity.
    Ng SY; Wilding JP
    Expert Opin Biol Ther; 2014 Aug; 14(8):1215-24. PubMed ID: 24905058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alström syndrome patients.
    Ali S; Baig S; Wanninayake S; da Silva Xavier G; Dawson C; Paisey R; Geberhiwot T
    Diabetes Obes Metab; 2024 Mar; 26(3):989-996. PubMed ID: 38151964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
    Tzotzas T; Karras SN; Katsiki N
    Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression.
    Wagner S; Brierley DI; Leeson-Payne A; Jiang W; Chianese R; Lam BYH; Dowsett GKC; Cristiano C; Lyons D; Reimann F; Gribble FM; Martinez de Morentin PB; Yeo GSH; Trapp S; Heisler LK
    Mol Metab; 2023 Feb; 68():101665. PubMed ID: 36592795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes.
    Ten Kulve JS; Veltman DJ; van Bloemendaal L; Barkhof F; Drent ML; Diamant M; IJzerman RG
    Diabetes Care; 2016 Feb; 39(2):214-21. PubMed ID: 26283736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment options for children with monogenic forms of obesity.
    Hainerová IA; Lebl J
    World Rev Nutr Diet; 2013; 106():105-12. PubMed ID: 23428688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system.
    Kaineder K; Birngruber T; Rauter G; Obermüller B; Eichler J; Münzker J; Al-Zoughbi W; Mautner SI; Torekov SS; Hartmann B; Kotzbeck P; Pieber TR
    Int J Obes (Lond); 2017 Aug; 41(8):1263-1270. PubMed ID: 28507313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.
    Jensterle M; Kocjan T; Kravos NA; Pfeifer M; Janez A
    Endocr Res; 2015; 40(3):133-8. PubMed ID: 25330463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liraglutide Treatment in a Morbidly Obese Adolescent with a
    Çamtosun E; Akıncı A; Kayaş L; Çiftçi N; Tekedereli İ
    J Clin Res Pediatr Endocrinol; 2023 May; 15(2):225-229. PubMed ID: 34584129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.
    Jensterle M; Salamun V; Kocjan T; Vrtacnik Bokal E; Janez A
    J Ovarian Res; 2015 Jun; 8():32. PubMed ID: 26032655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
    Lorenz M; Lawson F; Owens D; Raccah D; Roy-Duval C; Lehmann A; Perfetti R; Blonde L
    Cardiovasc Diabetol; 2017 Jan; 16(1):6. PubMed ID: 28086882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.
    Iepsen EW; Lundgren J; Dirksen C; Jensen JE; Pedersen O; Hansen T; Madsbad S; Holst JJ; Torekov SS
    Int J Obes (Lond); 2015 May; 39(5):834-41. PubMed ID: 25287751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liraglutide for Type 2 diabetes and obesity: a 2015 update.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Rev Cardiovasc Ther; 2015; 13(7):753-67. PubMed ID: 26106933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
    Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
    Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The contribution of serotonin 5-HT2C and melanocortin-4 receptors to the satiety signaling of glucagon-like peptide 1 and liraglutide, a glucagon-like peptide 1 receptor agonist, in mice.
    Nonogaki K; Suzuki M; Sanuki M; Wakameda M; Tamari T
    Biochem Biophys Res Commun; 2011 Jul; 411(2):445-8. PubMed ID: 21756875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.
    Svensson CK; Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Koyuncu K; Schjerning O; Nielsen J; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
    Acta Psychiatr Scand; 2019 Jan; 139(1):26-36. PubMed ID: 30374965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liraglutide: A Glucagon-Like Peptide-1 Agonist for Chronic Weight Management.
    Manigault KR; Thurston MM
    Consult Pharm; 2016 Dec; 31(12):685-697. PubMed ID: 28074747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.